

Candriam Sustainable Equity US

Market Overview

14 months on from its last interest rate hike, the Federal Reserve kickstarted its cutting cycle with a 50 basis point move in September. With the unemployment rate having drifted up from a low of 3.4% in April 2023 to 4.2% today, Fed officials have now made it clear that they do not welcome any further weakening in the economy and are keen to quickly move interest rates back to less restrictive levels. Later in the month, the Fed's more circumspect view on the economy was vindicated by the largest monthly decline in consumer confidence in over three years.

We witness conflicting signals from US firms. US private payroll growth has slowed, a typical recession indicator, but other signs like layoffs, equipment spending, and household purchasing power remain stable, with real wage gains supported by lower inflation. US indices closed the month higher (SPX +4.33%, INDU +3.48%, CCMP +6.22% and RTY +3.90).

Fund performance

In September, the fund returned 2.16%*, in line with its benchmark. The S&P 500 NR ended the period up by 2.10%**. Year-to-date, the fund underperforms its benchmark by 272bp, despite a positive absolute performance of 18.98%*.

Sector level

From a sector perspective, our stock selection added to the excess return (28bp) while allocation detracted (-16bp). Our selection in Financials (38bp) generated relative gains. Our stock selection in Health Care (-24bp) on the other hand, penalised the relative performance. The underweight in the Energy sector (17bp) added the most to the excess portfolio return.

Stock specific

With a positive impact of 10bp, the overweight of **HOME DEPOT INC** (Consumer Discretionary) was the main contributor to the excess portfolio return. The overweight of **ELEVANCE HEALTH INC** (Health Care) was the main detractor from the excess portfolio return, detracting by -8bp. Last month's best absolute performers were **GUIDEWIRE SOFTWARE INC** (Information Technology) and **TESLA INC** (Consumer Discretionary), which returned 23.0% and 22.2% respectively. Last month's worst absolute performers were **REGENERON PHARMACEUTICALS** (Health Care) and **ADOBE INC** (Information Technology), which returned -11.3% and -9.9% respectively.

Portfolio activity

In September, we introduced the three American companies, **ONTO INNOVATION INC** (Information Technology), **TENET HEALTHCARE CORP** (Health Care) and **C.H. ROBINSON WORLDWIDE INC** (Industrials) to our portfolio (+0.5%, +0.5% and +0.5% respectively). We also increased the positions of the two American firms, **ELI LILLY & CO** (Health Care) and **HOME DEPOT INC**, from 2.1% to 2.2% and from 1.9% to 2.3% respectively. We sold the three corporations from the United States, **FIRST SOLAR INC** (Information Technology), **DEXCOM INC** (Health Care) and **ALEXANDRIA REAL ESTATE EQUIT** (Real Estate) (-0.3%, -0.4% and -0.3% respectively). We also decreased the positions of the two American firms, **GUIDEWIRE SOFTWARE INC** and **NEUROCRINE BIOSCIENCES INC** (Health Care), from 0.5% to 0.1% and from 0.5% to 0.2% respectively.

* net of fees in USD terms



1

MONTHLY FUND COMMENT

September 2024



** net return in USD terms

Fund outlook

We see a clear trend towards a more sustainable world. Authorities around the world are taking the lead by changing regulations. Companies are taking active decisions by adjusting their business models to achieve a better ESG footprint. Consumers are taking ESG criteria into account when buying products and services, and investors are doing the same when evaluating alternatives to invest their wealth. In light of this trend, it is essential to take into account ESG criteria when making investment decisions. The objective of this strategy is to invest in companies that score well on both ESG and financial criteria. We believe that this type of company is well positioned to outperform the market in the long run.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change. In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws

and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage https://www.candriam.com/en/professional/market-insights/sfdr/. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may

be obtained free of charge from the Swiss representative

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35,

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 1493

